Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 11/20 | 0.96 |
| ▸ | CSNK2B | P67870 | 11/20 | 0.96 |
| ▸ | CSNK2A1 | P68400 | 11/20 | 0.96 |
| ▸ | PRKCA | P17252 | 7/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.42 |
| ▸ | PRKCG | P05129 | 2/20 | 0.42 |
| ▸ | PRKCB | P05771 | 2/20 | 0.42 |
| ▸ | PRKCH | P24723 | 2/20 | 0.42 |
| ▸ | PRKCI | P41743 | 2/20 | 0.42 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.42 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.42 |
| ▸ | CSNK1G2 | P78368 | 2/20 | 0.42 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.42 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.42 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.42 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.42 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7230124 | 0.98 | CSNK2A2 (0.93) | CSNK2A2CSNK2BCSNK2A1PRKCAMEN1 | |
| SCHEMBL7525776 | 0.81 | CSNK2A2 (0.97) | CSNK2A2CSNK2BCSNK2A1PRKCAMEN1 | |
| SCHEMBL7526640 | 0.81 | CSNK2A2 (0.75) | CSNK2A2CSNK2BCSNK2A1PRKCAMEN1 | |
| SCHEMBL11921342 | 0.77 | CSNK2A2 (0.96) | CSNK2A2CSNK2BCSNK2A1PRKCAMEN1 | |
| SCHEMBL12775850 | 0.77 | CSNK2A2 (0.61) | CSNK2A2CSNK2BCSNK2A1PRKCAMEN1 | |
| SCHEMBL11921339 | 0.74 | CSNK2A2 (0.97) | CSNK2A2CSNK2BCSNK2A1PRKCAPRKD3 | |
| SCHEMBL7522608 | 0.74 | CSNK2A2 (0.97) | CSNK2A2CSNK2BCSNK2A1PRKCAMEN1 | |
| SCHEMBL8739989 | 0.69 | CSNK2A2 (0.50) | CSNK2A2CSNK2BCSNK2A1MAPTSMN1; SMN2 | |
| SCHEMBL8521833 | 0.69 | CSNK2A2 (0.50) | CSNK2A2CSNK2BCSNK2A1PRKCAPRKD3 | |
| SCHEMBL7521847 | 0.67 | CSNK2A2 (0.53) | CSNK2A2CSNK2BCSNK2A1KMT2ARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242136-B2 | Use of glucosidase inhibitors for therapy of mucovisidosis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2012-08-14 | — | — | US | disclosed |
| US-20110269795-A1 | USE OF GLUCOSIDASE INHIBITORS FOR THERAPY OF MUCOVISIDOSIS | UNIVERSITE DE POITIERS (FR) | 2011-11-03 | — | — | US | disclosed |
| US-7973054-B2 | Use of glucosidase inhibitors for therapy of mucovisidosis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2011-07-05 | — | — | US | disclosed |
| US-7897610-B2 | hypertension and asthma; vasorelaxants | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2011-03-01 | — | — | US | disclosed |
| US-7772198-B2 | CFTR channel modulators | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-08-10 | — | — | US | disclosed |
| US-20070213357-A1 | Use of Glucosidase Inhibitors for Therapy of Mucovisidosis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2007-09-13 | — | — | US | disclosed |
| US-6630482-B1 | Cystic fibrosis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2003-10-07 | — | — | US | disclosed |
| EP-0937044-B1 | CFTR CHANNEL ACTIVATOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | CENTRE NAT RECH SCIENT (FR) | 2002-01-30 | — | — | EP | disclosed |
| EP-0937044-A1 | CFTR CHANNEL ACTIVATOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1999-08-25 | — | — | EP | disclosed |
| WO-1998005642-A1 | CFTR CHANNEL ACTIVATOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1998-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269795-A1 | USE OF GLUCOSIDASE INHIBITORS FOR THERAPY OF MUCOVISIDOSIS | MAN2B1, GAA, MAN2A1 | CSNK2A2 787/4885CSNK2B 947/4885CSNK2A1 769/4885 |
| US-20070213357-A1 | Use of Glucosidase Inhibitors for Therapy of Mucovisidosis | MAN2B1, GAA, MAN2A1 | CSNK2A2 677/4885CSNK2B 818/4885CSNK2A1 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.